基本信息
浏览量:8
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Cancer arises through the accumulation of genetic and epigenetic alterations that promote the altered phenotypes that result in a heterogeneous collection of disease states. By elucidating the molecular mechanisms that drive these cancer phenotypes, we acquire a more detailed understanding of the tumorigenic process and in turn, better insight into how cancer can be treated.
My research utilizes functional genomics approaches to uncover and characterize mechanisms of tumorigenesis and tumor maintenance, with the ultimate goal of identifying potential therapeutic targets for cancer. To this end, I use high-throughput technologies coupled with RNAi and open-readingframe (ORF) expression libraries to perform functional characterization in a systematic and comprehensive manner. Current projects include use of loss-of-function RNAi screening approaches to identify genes essential for cancer cell proliferation and survival, as they provide points of vulnerability of the cancer and may translate directly to drug targets. Moreover, by performing synthetic-lethal screens, we can identify those genes that are essential only in specific contexts, for example in the presence of specific oncogenic mutations or aberrantly activated signaling pathways. This approach may be of particular clinical relevance, as it provides both a specific drug target and a biomarker to identify patients most likely to respond, facilitating the development of personalized, molecularly targeted therapy. Other projects currently ongoing include gain-of-function ORF screens to identify (1) modifiers of chemotherapeutic drug response and (2) regulators of signaling pathways commonly activated during tumorigenesis.
One strategy that has been particularly productive in recent years in the identification of novel cancer-relevant genes and mechanisms is the integration of high throughput functional approaches with large-scale efforts to enumerate all the structural alterations recurrently found in cancer genomes. By comparing these two complementary sets of data, we can rapidly identify which of the structural alterations actually contribute directly to the oncogenically transformed state, i.e. driver mutations. This information is of clinical importance, as previous experience has shown that many tumors are oncogene-addicted and some of the most effective cancer therapies are those that target an oncogenic driver, such as the BCR/ABL translocation in CML, ERBB2 amplification in breast cancer or EGFR mutation in lung cancer. My research aims to continue leveraging both functional and structural information of the cancer genome, which is currently being generated at a tremendous pace, to gain new mechanistic insights into cancer.
My research utilizes functional genomics approaches to uncover and characterize mechanisms of tumorigenesis and tumor maintenance, with the ultimate goal of identifying potential therapeutic targets for cancer. To this end, I use high-throughput technologies coupled with RNAi and open-readingframe (ORF) expression libraries to perform functional characterization in a systematic and comprehensive manner. Current projects include use of loss-of-function RNAi screening approaches to identify genes essential for cancer cell proliferation and survival, as they provide points of vulnerability of the cancer and may translate directly to drug targets. Moreover, by performing synthetic-lethal screens, we can identify those genes that are essential only in specific contexts, for example in the presence of specific oncogenic mutations or aberrantly activated signaling pathways. This approach may be of particular clinical relevance, as it provides both a specific drug target and a biomarker to identify patients most likely to respond, facilitating the development of personalized, molecularly targeted therapy. Other projects currently ongoing include gain-of-function ORF screens to identify (1) modifiers of chemotherapeutic drug response and (2) regulators of signaling pathways commonly activated during tumorigenesis.
One strategy that has been particularly productive in recent years in the identification of novel cancer-relevant genes and mechanisms is the integration of high throughput functional approaches with large-scale efforts to enumerate all the structural alterations recurrently found in cancer genomes. By comparing these two complementary sets of data, we can rapidly identify which of the structural alterations actually contribute directly to the oncogenically transformed state, i.e. driver mutations. This information is of clinical importance, as previous experience has shown that many tumors are oncogene-addicted and some of the most effective cancer therapies are those that target an oncogenic driver, such as the BCR/ABL translocation in CML, ERBB2 amplification in breast cancer or EGFR mutation in lung cancer. My research aims to continue leveraging both functional and structural information of the cancer genome, which is currently being generated at a tremendous pace, to gain new mechanistic insights into cancer.
研究兴趣
论文共 235 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Valerie U. Nguyen,Laurie Graves, Veronica Colmenares, Abol Macabangon, Casey Syal, Kelsey Fisher-Wellman,William C. Eward,So Young Kim,Jason A. Somarelli
Cancer Researchno. 6_Supplement (2024): 1085-1085
SCIENTIFIC REPORTSno. 1 (2024): 7410-7410
COMMUNICATIONS IN STATISTICS-THEORY AND METHODSpp.1-19, (2024)
Haematologicano. 7 (2023): 1900-1908
Biometricsno. 4 (2023): 3916-3928
Bone marrow transplantationno. 1 (2023): 76-84
Transplantation and cellular therapyno. 1 (2023): 114.e1-114.e16
Jason A. Somarelli,Roham Salman Roghani,Ali Sanjari Moghaddam,Beatrice C. Thomas,Gabrielle Rupprecht,Kathryn E. Ware,Erdem Altunel, John B. Mantyh,So Young Kim,Shannon J. McCall,Xiling Shen, Christopher R. Mantyh,
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn